Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.

Jay Woods, chief global strategist at Freedom Capital Markets, said sectors such as energy and materials often lead near market tops, making them an unusual foundation for sustained rallies. "These ...

How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and ...

Halozyme Therapeutics is entering a powerful earnings inflection. FY25 revenue grew 38% to $1.397 billion. Check out why I am bullish on HALO stock.

Halozyme Therapeutics HALO reported fourth-quarter 2025 adjusted loss of 24 cents per share against the Zacks Consensus Estimate of earnings of $2.15. The company had reported adjusted earnings of $1.

The planemaker is continuing to innovate with its cabins.

Machado-Joseph disease causes sufferers to struggle with speech and movement as they lose control of their bodies.

MotoGP is on a mission to establish the motorsport as a “rock and roll” brand as it looks to ingrain itself into sports culture and appeal to a wider audience.

Consumer Analyst Group of New York Conference 2026 February 18, 2026 10:00 AM ESTCompany ParticipantsJacek Olczak ...

A documentary film about First Lady Melania Trump surprised movie experts with a strong opening weekend at the box office ...

Released via specialist video game soundtrack label Laced Records, Clair Obscur: Expedition 33 OST debuted at No.16 (5,322 units), according to the Official Charts Company. The album was released ...

Between American president Donald Trump’s chaotic, fly-by-night tariff strategy and the ever-rising power demands of AI technology, it has long ...